Ovid Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Cash Discipline LMRI Q1 2026 Earnings EPS Surges Past Expectations by 45 Stock Edges Lower SFL Q1 2026 Earnings Monumental EPS Surprise Overshadowed by Share Decline CIG Q1 2026 Earnings EPS Beat Fails to Ignite Stock as Revenue Details Remain Absent DLR Q1 2026 Earnings Slight EPS Beat Amid Data Center Demand WTW Q1 2026 Earnings Modest EPS Beat Masks Subdued Market Sentiment